NCT04253483 - Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions

Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8

Interventions

RADIATION

High-Dose Rate Brachytherapy

Undergo HDR

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Stereotactic Ablative Radiotherapy

Undergo SABR

Trial Locations (3)

07039

RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

07101

Rutgers New Jersey Medical School, Newark

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER